Myelodysplastic syndromes. | Aplastic Anemia and MDS International Foundation

Myelodysplastic syndromes.

Journal Title: 
Annu Rev Med
Author(s): 
Scott BL, Deeg HJ
Primary Author: 
Scott BL
Original Publication Date: 
Friday, January 1, 2010

Myelodysplastic syndromes (MDS) represent a collection of stem cell disorders characterized by impaired hematopoiesis resulting in low peripheral blood counts. The majority of patients with MDS present with symptoms related to anemia; however, bleeding and infection are the most common causes of death. The median age of diagnosis is 72 and the median survival is 2.5 years. Lenalidomide, azacitidine, and decitabine are all FDA-approved agents to treat MDS; however, the only potential cure for MDS remains stem cell transplantation.

Bone Marrow Diseases: